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Summary
Background Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion 
of adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity of imaging characteristics. 
We aimed to validate a urine steroid metabolomics approach, using steroid profiling as the diagnostic basis for ACC.
Methods We did a prospective multicentre study in adult participants (age ≥18 years) with newly diagnosed adrenal 
masses. We assessed the accuracy of diagnostic imaging strategies based on maximum tumour diameter (≥4 cm vs 
<4 cm), imaging characteristics (positive vs negative), and urine steroid metabolomics (low, medium, or high risk of 
ACC), separately and in combination, using a reference standard of histopathology and follow-up investigations. With 
respect to imaging characteristics, we also assessed the diagnostic utility of increasing the unenhanced CT tumour 
attenuation threshold from the recommended 10 Hounsfield units (HU) to 20 HU. 
Findings Of 2169 participants recruited between Jan 17, 2011, and July 15, 2016, we included 2017 from 14 specialist 
centres in 11 countries in the final analysis. 98 (4·9%) had histopathologically or clinically and biochemically 
confirmed ACC. Tumours with diameters of 4 cm or larger were identified in 488 participants (24·2%), including 
96 of the 98 with ACC (positive predictive value [PPV] 19·7%, 95% CI 16·2–23·5). For imaging characteristics, 
increasing the unenhanced CT tumour attenuation threshold to 20 HU from the recommended 10 HU increased 
specificity for ACC (80·0% [95% CI 77·9–82·0] vs 64·0% [61·4–66.4]) while maintaining sensitivity (99·0% 
[94·4–100·0] vs 100·0% [96·3–100·0]; PPV 19·7%, 16·3–23·5). A urine steroid metabolomics result indicating high 
risk of ACC had a PPV of 34·6% (95% CI 28·6–41·0). When the three tests were combined, in the order of tumour 
diameter, positive imaging characteristics, and urine steroid metabolomics, 106 (5·3%) participants had the result 
maximum tumour diameter of 4 cm or larger, positive imaging characteristics (with the 20 HU cutoff), and urine 
steroid metabolomics indicating high risk of ACC, for which the PPV was 76·4% (95% CI 67·2–84·1). 70 (3·5%) 
were classified as being at moderate risk of ACC and 1841 (91·3%) at low risk (negative predictive value 99·7%, 
99·4–100·0).
Interpretation An unenhanced CT tumour attenuation cutoff of 20 HU should replace that of 10 HU for exclusion of 
ACC. A triple test strategy of tumour diameter, imaging characteristics, and urine steroid metabolomics improves 
detection of ACC, which could shorten time to surgery for patients with ACC and help to avoid unnecessary surgery 
in patients with benign tumours.
Funding European Commission, UK Medical Research Council, Wellcome Trust, and UK National Institute for Health 
Research, US National Institutes of Health, the Claire Khan Trust Fund at University Hospitals Birmingham Charities, 
and the Mayo Clinic Foundation for Medical Education and Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
Adrenal masses are discovered incidentally in about 
5% of cross-sectional imaging examinations.1,2 The 
prevalence of these so-called inciden talomas increases 
with age and is estimated to be about 3% among people 
aged 40 years and 10% among those aged 70 years.3 
Because of widespread use of CT and MRI, the number 
of adrenal incidentalomas identified is increasing 
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worldwide. In the USA, more than 100 million CT and 
MRI examinations are done per year,4 which could 
potentially reveal around 5 million adrenal masses. 
Diagnostic assessment and therapeutic management of 
incidentalomas is a challenging health-care issue.5,6
The discovery of an adrenal mass prompts two major 
questions to be addressed by the diagnostic investi-
gations. The first question is whether the tumour causes 
adrenal hormone excess, which requires exclusion of 
pheochromo cytoma, Cushing’s syndrome, and primary 
aldoste ronism via biochemical testing.7–9 The second 
question is whether the adrenal mass is an adrenocortical 
carcinoma (ACC). These tumours account for 2–12% of 
adrenal incidentalomas.10–13 Prognosis of ACC is poor and 
cure is achievable only with early detection and surgery.14 
Multimodal and repeated imaging is routinely used to 
detect and exclude ACC, despite an insufficient evidence 
base to support this approach due to small studies in 
heterogeneous popu lations and with poor reference 
standards.15 Based on available data, an unenhanced 
CT tumour attenuation of less than 10 Hounsfield units 
(HU) is thought to be indicative of a lipid-rich mass, 
which is a common characteristic of benign adrenal 
tumours.15 European guidelines, therefore, recommend 
that unenhanced CT should be the primary imaging test 
to exclude ACC.16 However, the 10 HU cutoff has poor 
specificity for malignancy because of the existence of 
many lipid-poor benign adrenal masses.11,15,17 Patients 
therefore frequently undergo repeated imaging by 
multiple modalities and the unneces sary surgical removal 
of adrenal masses that are revealed postoperatively to be 
benign.10,11
Urine steroid metabolomics is the combination of 
mass spectrometry-based urinary steroid metabolite 
Research in context
Evidence before this study
The discovery of an adrenal mass requires further assessment to 
determine whether the tumour is a malignant adrenocortical 
carcinoma (ACC) or a benign adrenocortical adenoma (ACA). 
Imaging tests are the mainstay in detection of ACC, but the 
available methods have poor diagnostic accuracy. In 2016 we 
did a systematic review and meta-analysis of the accuracy of 
imaging modalities. We searched MEDLINE, Embase, the 
Cochrane Central Register of Controlled Trials, the Science 
Citation Index, the Conference Proceedings Citation Index, and 
Zetoc for reports published from Jan 1, 1990, to Aug 31, 2015, 
to identify all studies that had assessed the diagnostic accuracy 
of imaging methods employed in the differential diagnosis of 
adrenal masses (CT, MRI, and ¹⁸F-fluorodeoxyglucose [¹⁸F-FDG] 
PET) in comparison with histology or imaging-based follow-up 
as the reference standard. The search terms used for these 
database searches were reported in that study. Based on data 
from only two eligible studies involving 102 participants, an 
unenhanced CT tumour attenuation value of more than 
10 Hounsfield units (HU) was shown to have high sensitivity 
(100%) but poor specificity (72%) for the detection of ACC. 
Studies assessing ¹⁸F-FDG PET, MRI with chemical shift analysis, 
and CT with contrast washout had even smaller sample sizes 
(n=25–75) and generated sensitivity and specificity estimates 
with very wide CIs. In 2019 we updated our previous search 
with a PubMed search using the same search terms and 
covering the dates Sept 1, 2015−Jan 31, 2019. We found no 
studies that altered the conclusions of the 2016 systematic 
review and meta-analysis, nor any newly published meta-
analyses addressing the same question. We did a retrospective 
proof-of-principle study in 45 participants with ACC and 
102 with ACA, in which we showed that urine steroid 
metabolomics (ie, mass spectrometry-based steroid metabolite 
profiling of 24 h urine samples combined with machine-
learning-based data analysis) could detect ACC with high 
sensitivity and specificity. Although similar diagnostic 
accuracies were reported in several other retrospective studies, 
we did not identify any previous prospective test validation 
studies.
Added value of this study
In this prospective, multicentre, test validation study, 
we assessed the diagnostic accuracy of urine steroid 
metabolomics for the detection of ACC in patients with newly 
diagnosed adrenal masses compared with routinely employed 
imaging strategies (measurement of tumour size and 
assessment of imaging characteristics). As a single test, urine 
steroid metabolomics had a higher positive predictive value 
(PPV) than either imaging test (34·6% [95% CI 28·6–41·0] vs 
19·7% [16·2–23·5] for tumour size and 19·7% [16·3–23·5] for 
imaging characteristics). Additionally, in a comparison with the 
standarad cutoff of 10 HU for unenhanced CT tumour 
attenuation, a cutoff of 20 HU increased specificity from 64% 
to 80% while sensitivity remained similar. The best diagnostic 
performance was provided by the combination of tumour 
diameter greater than 4 cm, unenhanced CT tumour 
attenuation greater than 20 HU, and urine steroid 
metabolomics indicating a high risk of ACC, which provided a 
PPV of 76·4% and a negative predictive value of 99·7% for ACC.
Implications of all the available evidence
This study prospectively validated the diagnostic accuracy of 
urine steroid metabolomics seen in retrospective studies. Use 
of radiation-free, non-invasive urine steroid metabolomics has 
a higher PPV than two standard imaging tests, and best 
performance was seen with the combination of all three tests. 
Implementation of urine steroid metabolomics in the routine 
diagnostic assessment of newly discovered adrenal masses 
could reduce the number of imaging procedures required to 
diagnose ACC and avoid unnecessary surgery of benign adrenal 
tumours, potentially yielding beneficial effects with respect to 
patient burden and health-care costs.
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profiling and machine-learning-based data analysis. In a 
retrospective proof-of-principle study, we showed that 
this approach was highly promising for the detection of 
ACC, with high sensitivity (90%) and specificity (88%).18 
Similar findings were reported in several subsequent 
retrospective studies.19–21
To validate the use of urine steroid metabolomic testing 
in this context, we did the prospective, multicentre 
Evaluation of Urine Steroid Metabolomics in the 
Differential Diagnosis of Adrenocortical Tumours 
(EURINE-ACT) study in adult participants with newly 
diagnosed adrenal masses. We investigated the diagnostic 
accuracy of urine steroid metabolomics alone and in 
combination with standard imaging protocols, and 
compared our findings with histopathology and clinical 
and imaging follow-up investigations as the reference 
standard. 
Methods
Study design and participants
EURINE-ACT was a prospective test validation study 
performed according to the STARD guidelines for studies 
of diagnostic accuracy (appendix pp 36–37) and done in 
adult participants (age ≥18 years) with a newly identified 
adrenal mass of more than 1  cm diameter. Exclusion 
criteria were biochemical evidence of pheochromocytoma 
(appendix p 5), pregnancy, lactation, and current or 
recent (<6 months) intake of drugs known to alter 
steroid synthesis or metabolism. Patients with an adrenal 
mass discovered during imaging for cancer staging or 
monitoring were also not eligible.
Participants were recruited through specialist centres 
participating in the European Network for the Study of 
Adrenal Tumours ([ENSAT]; appendix p 4) . The study was 
advertised to all ENSAT members, and 21 centres in 
14 countries (Brazil, Croatia, France, Germany, Greece, 
Ireland, Italy, the Netherlands, Norway, Poland, Portugal, 
Serbia, the UK, and the USA) agreed to participate and 
initi ated enrolment. We asked centres to recruit 
prospectively consecutive eligible individuals willing to 
participate (ie, non-selective recruitment), from 
Jan 17, 2011, to July 15, 2016.
All participating centres obtained local ethics approval 
for recording of pseudonymised and standardised data in 
the ENSAT registry relevant to the study (demographic 
characteristics, method of tumour identification, tumour 
diameter and imaging characteristics, endocrine testing 
results, clinical and radiological follow-up data, surgery 
details, and histopathology data) and for collection and use 
of participant-related biomaterial (appendix pp 4–5). All 
participants provided written informed consent before 
inclusion. 
Reference standard
The reference standard for ACC was based on 
histopathology or, alternatively, the presence of a large 
adrenal tumour and mixed steroid excess typical of ACC, 
with no other feasible alternative diagnosis. Adrenal 
masses were classified as benign based on histopathology 
after surgical removal, or, in those not removed, by lack 
of growth on imaging after 6 months or clinical folllow-
up of at least 12 months (appendix p 23).
Imaging assessments
Diagnostic investigation for adrenal tumours by imaging 
was done as part of routine care at the clinical centres in 
accordance with their standard guidelines. Local centres 
made decisions about the need for adrenalectomy (and in 
rare cases adrenal biopsy) based on imaging, without any 
access to urine steroid metabolomics data. The imaging 
index tests we recorded were maximum tumour diameter 
at the time of discovery and imaging characteristics. 
Tumour diameter of 4 cm or greater indicated suspicion 
of ACC.10
Imaging characteristics regarded as suspicious of 
ACC11,15 were as follows (in order of ranking15): unenhanced 
CT tumour tissue attenuation (<10 HU, 10–20 HU, or 
>20 HU in homogeneous tumours or heterogeneous 
tumours precluding HU measurement); MRI chemical 
shift analysis with no loss of signal intensity in the tumour 
area on out-of-phase images; ¹⁸F-fluorodeoxyglucose 
(¹⁸F-FDG) PET with a tumour standardised uptake value 
higher than that in the liver; follow-up imaging showing 
an increase of the maximum diameter of at least 20% 
6 months or more after the index scan; and CT contrast 
washout assessment showing absolute contrast washout 
from less than 60% of the tumour area. If participants 
underwent multiple imaging modalities, a positive or 
negative result for ACC was based on the highest ranking 
imaging characteristic reported.
Urine steroid metabolomics testing
Enrolled participants collected a 24 h urine sample 
that was used for multisteroid profiling by liquid 
chromatography–tandem mass spectrometry (LC–MS/MS), 
with quantification of 15 urinary steroid metabolites 
(appendix p 19) and application of a machine-learning 
algorithm.
The algorithm was developed by applying generalised 
matrix learning vector quantisation18 to steroid excretion 
data from a retrospective cohort of 139 patients with 
adrenal masses (40 ACC and 99 adrenocortical adenoma 
[ACA]) measured retrospectively by use of the LC–MS/
MS method used in this study (appendix pp 7–9). Based 
on the distances of the entirety of the steroid metabolome 
of ACC and ACA prototypes, the generalised matrix 
learning vector quantisation classifier provides a test 
outcome score. The corresponding thresholds were 
selected to ensure the post-test probability of ACC was 
greater than 65% in the high-risk group and less than 
10% in the low-risk group, giving a moderate risk range 
of 10−65% (appendix p 9).
Urine steroid metabolomics analyses were done after 
all routine tests in the study centres were completed, but 
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without access to the reference standard findings or 
other diagnostic information. This timing also prevented 
urine steroid metabolomics results being communicated 
to the study centres and affecting the normal diagnostic 
process.
Statistical analysis
We aimed to include 2000 participants and expected an 
ACC rate of 5%, based on the results of our proof-of-
principle study (appendix p 4), and loss to follow-up of 
10%.18 We calculated that observing 100 ACC cases would 
provide 95% sensitivity with a 95% CI range of less than 
10% and more than 99% power to detect a difference of 
3% in specificity (87% vs 90%) between standard imaging 
protocols and urine steroid metabolomics at the 
5% significance level. 
Characteristics of participants are reported for each 
type of tumour assessed (ACC, other malignant tumours, 
ACA, and other benign tumours), with data presented 
as median (IQR) for categorical results or number (%) 
for continuous data. For each diagnostic test (maximum 
tumour diameter [≥4 cm vs <4], imaging characteristics 
[positive vs negative], or urine steroid metabolomics [low, 
medium, or high risk of ACC]), we computed the 
percentage of ACC cases with each test result (giving 
sensitivity for a positive result in the binary tests); the 
percentage of non-ACC cases with each test result (giving 
specificity for a negative result in the binary tests); and 
the likelihood ratio for each test result. Additionally, 
we assessed the tests in combinations of two (tumour 
diameter plus imaging characteristics, tumour diameter 
plus urine steroid metabolomics, and imaging 
characteristics plus urine steroid metabolomics) and as a 
triple test strategy (tumour diameter, followed by imaging 
characteristics followed by urine steroid metabolomics). 
We also calculated the proportions of participants with 
ACC who had each test result to estimate the probability 
of ACC (ie, positive predictive value [PPV] for positive 
results and 1 minus negative predictive value [NPV] for 
negative test results). All results are reported with 
95% CIs, computed by use of the exact binomial method 
for proportions and the Wald-based methods for 
likelihood ratios. Finally, we investigated the diagnostic 
utility of increasing the unenhanced CT tumour 
attenuation threshold from the recommended 10 HU to 
20 HU. 
For urine steroid metabolomics, we calculated the area 
under the receiver operating characteristic curve 
(AUROC) with 95% CIs. A sensitivity analysis was done 
that excluded participants with ACC who had mixed or 
aberrant steroid excess, clinical presentation of large 
adrenal mass with extra-adrenal metastases, or bilateral 
macronodular adrenal hyperplasia and isolated cortisol 
excess identifying presumed benign tumours.
All statistical analyses were done with Stata version 16 
and graphs were created in R.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Jan 17, 2011, and July 15, 2016, 2169 eligible 
participants were recruited from the 21 participating 
centres and provided 24 h urine samples (figure 1, 
appendix p 14). However, review of the data showed that 
only 14 of the 21 centres had a high median annual 
recruitment rate (33 participants per year) and a median 
centre-specific proportion of ACC of 3·9%. These 
14 centres recruited a total of 2068 participants. By 
contrast, the seven remaining centres jointly recruited 
only 101 participants (median annual recruitment 
rate 6·7), but the median proportion of ACC cases was 
35% (appendix p 21). Investigators at these seven sites 
confirmed that they had recruited selectively, favouring 
large and suspicious masses, compared with non-
selective consecutive recruitment at the other 14 centres. 
Therefore, we excluded the 101 participants from these 
seven centres. An additional 51 participants were 
excluded from the analysis because of sample loss during 
storage, transport, or processing; therefore, the final 
analysis cohort consisted of 2017 participants (figure 1). 
No participants were lost to follow-up. 
The median age of included participants was 59 years, 
62% were women, and 84% of the adrenal tumours were 
discovered incidentally (table 1). Diagnosis by the reference 
standards was ACC in 98 (4·9%), other malignant tumours 
in 65 (3·2%), ACA in 1767 (87·6%), and other benign 
tumours in 87 participants (4·3%; table 1, appendix 
pp 11, 22). Histopathology results were used to provide the 
diagnosis for 91 (92·9%) of the ACCs, 65 (100·0%) of other 
malignant tumours, 370 (20·9%) of ACAs, and 59 (67·8%) 
of other benign tumours. Clinical and radiological follow-
up assessments were used to provide the diagnosis for all 
remaining tumours (appendix p 23).Figure 1: Study profile
2169 patients with newly diagnosed adrenal tumours and 
 24 h urine sample collected at diagnosis
101 patients excluded due to selective 
 recruitment
2068 patients enrolled
51 patients excluded due to sample loss 
2017 patients included in final analysis
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563 (27·9%) of 2017 participants underwent adrenalec-
tomy, including 370 with ACA and 59 with other benign 
tumours (appendix p 22). 186 of these ACAs (50·3%) 
were either non-functioning (n=81) or showed only 
mild autonomous cortisol secretion (n=105). Thus, 
245 (43·5%) of 563 surgically managed participants 
would not have required adrenalectomy. Even if mild 
autonomous cortisol secretion was used as an indication 
for adrenalectomy, which is not current clinical practice, 
140 (24·9%) of 563 adrenal masses would still have not 
required adrenalectomy.
2737 imaging tests were done in the 2017 participants 
(appendix p 18). A tumour diameter of at least 4 cm was 
seen in most participants with ACC and other malignant 
tumours, around two-thirds of those with other benign 
tumours and nearly 17% of those with ACA (table 1, 
figure 2, appendix p 24). The highest-ranking imaging 
characteristics results were obtained by unenhanced CT 
in 1549 (76·8%), MRI chemical shift analysis in 
227 (11·3%), ¹⁸F-FDG PET in 43 (2·1%), follow-up CT in 
155, and CT contrast washout assessment in six 
participants (appendix p 18). All 98 participants with ACC 
had homogeneous tumours with unenhanced CT tumour 
attenuation of at least 10 HU or heterogeneous tumours 
precluding HU measurement (table 1). However, among 
1328 participants with ACA, unen hanced CT attenuation 
was greater than the cutoff of 10 HU (ie, false positive) in 
423 participants (31·9%; table 1). With attenuation greater 
than 20 HU, 97 (99%) participants with ACC remained 
true positive and false-positive results in ACAs decreased 
to 200 (15·1%). This change in cutoff from 10 HU to 
20 HU therefore improved the specificity for ACC from 
64·0% (95% CI 61·4–66.4) to 80·0% (77·9–82·0; 
appendix p 24). Changing the cutoff from 10 to 20 HU 
improved specificity across the whole study cohort 
(figure 2, appendix p 24). For the other imaging modalities, 
false-positive results in ACAs were seen in 65 (20·8%) of 
312 participants with MRI, four (3·1%) of 127 with 
¹⁸F-FDG PET, and six (1·0%) of 617 with follow-up CT. 
Tumour diameter and imaging characteristics yielded 
similar PPVs and NPVs for ACC (table 2, appendix p 24).
The accuracy of urine steroid metabolomics was high 
(AUROC 94·6%, 95% CI 92·2–96·9; appendix p 29). 
Urine steroid metabolomics profiles indi cating high risk 
of ACC were seen in 83 (84·7%) of 98 participants with 
ACC and 157 (8·2%) of 1919 with non-ACC masses 
(table 2, appendix p 29). High risk of ACC indicated by 
urine steroid metabolomics substantially improved PPV 
compared with imaging tests, while a low-risk score had 
similar ability to imaging tests to rule out ACC (table 2). A 
urine steroid metabolomics profile indicating moderate 
risk of ACC (n=668 [33·1%]) was associated with a PPV of 
1·9% (table 2).
Cross-tabulation of urine steroid metabolomics results 
against results obtained with the three most frequently 
used imaging modalities—unenhanced CT, MRI chemical 
shift, and ¹⁸F-FDG PET—showed that high risk of ACC 
ACC 
(n=98)
Other 
malignant 
tumours (n=65)
ACA 
(n=1767)
Other benign 
tumours 
(n=87)
Total 
(n=2017)
Sex
Men 37 (37·8%) 38 (58·5%) 663 (37·5%) 37 (42·5%) 775 (38·4%)
Women 61 (62·2%) 27 (41·5%) 1104 (62·5%) 50 (57·5%) 1242 (61·6%)
Age at diagnosis 
(years)
50 (42–61) 64 (53–70) 59 (50–67) 52·5 (44–62) 59 (49–67)
Incidentally discovered
Yes 43 (43·9%) 56 (86·2%) 1513 (85·6%) 74 (85·1%) 1686 (83·6%)
No* 55 (56·1%) 9 (13·8%) 254 (14·4%) 13 (14·9%) 331 (16·4%)
Location of tumour
Right adrenal 38 (38·8%) 23 (35·4%) 556 (31·5%) 43 (49·4%) 660 (32·7%)
Left adrenal 60 (61·2%) 35 (53·8%) 843 (47·7%) 35 (40·2%) 973 (48·2%)
Both adrenals 0 7 (10·8%) 368 (20·8%) 9 (10·3%) 384 (19·0%)
Maximum tumour 
diameter (cm)
9·6  
(6·5–13·5)
6·5  
(3·7–10·0)
2·5  
(1·7–3·5)
4·7  
(2·7–7·0)
2·7  
(1·8–3·9)
<2 0 6 (9·2%) 559 (31·6%) 11 (12·6%) 576 (28·6%)
2 to <4 2 (2·0%) 13 (20·0%) 912 (51·6%) 26 (29·9%) 953 (47·2%)
≥4 96 (98·0%) 46 (70·8%) 296 (16·8%) 50 (57·5%) 488 (24·2%)
Unenhanced CT tumour attenuation
<10 HU† 0 0 905 (51·2%) 23 (26·4%) 928 (46·0%)
10–20 HU† 1 (1·0%) 1 (1·5%) 223 (12·6%) 9 (10·3%) 234 (11·6%)
>20 HU‡ 32 (32·7%) 38 (58·5%) 200 (11·3%) 30 (34·5%) 300 (14·9%)
Heterogeneous§ 65 (66·3%) 21 (32·3%) 0 1 (1·1%) 87 (4·3%)
Not done 0 5 (7·7%) 439 (24·8%) 24 (27·6%) 468 (23·2%)
MRI
Chemical shift 
present†
0 1 (1·5%) 247 (14·0%) 5 (5·7%) 253 (12·5%)
Chemical shift 
absent‡
1 (1·0%) 8 (12·3%) 65 (3·7%) 15 (17·2%) 89 (4·4%)
Not done 97 (99·0%) 56 (86·2%) 1455 (82·3%) 67 (77·0%) 1675 (83·0%)
¹⁸F-FDG PET
Low uptake† 0 0 123 (7·0%) 10 (11·5%) 133 (6·6%)
High uptake‡ 2 (2·0%) 17 (26·2%) 4 (0·2%) 5 (5·7%) 28 (1·4%)
Not done 96 (98·0%) 48 (73·8%) 1640 (92·8%) 72 (82·8%) 1856 (92·0%)
CT absolute contrast washout
≥60%† 0 0 19 (1·1%) 0 19 (0·9%)
<60%‡ 0 0 2 (0·1%) 0 2 (0·1%)
Not done 98 (100·0%) 65 (100·0%) 1746 (98·8%) 87 (100·0%) 1996 (99·0%)
Maximum diameter on CT after ≥6 months
Stable or reduced† 0 5 (7·7%) 611 (34·6%) 26 (29·9%) 642 (31·8%)
Increased >20%‡ 0 8 (12·3%) 6 (0·3%) 8 (9·2%) 22 (1·1%)
Not done 98 (100·0%) 52 (80·0%) 1150 (65·1%) 53 (60·9%) 1353 (67·1%)
Invasive intervention
Adrenalectomy 84 (85·7%) 50 (76·9%) 370 (20·9%) 59 (67·8%) 563 (27·9%)
Biopsy 7 (7·1%) 11 (16·9%) 0 0 18 (0·9%)
None 7 (7·1%) 4 (6·2%) 1397 (79·1%) 28 (32·2%) 1436 (71·2%)
Data are n (%) or median (IQR). ACC=adrenocortical carcinoma. ACA=adrenocortical adenoma. HU=Hounsfield units. 
¹⁸F-FDG=¹⁸F-fluorodeoxyglucose. *Non-incidental modes of discovery included adrenal masses discovered after 
imaging done for either clinical signs and symptoms indicative of possible steroid excess or suggestive of a tumour 
(ie, mass effect with abdominal discomfort or symptoms with weight loss, low grade fever, or both). †Negative for 
ACC. ‡Positive for ACC. §HU could not be reliably measured and the tumour was classified as positive.
Table 1: Clinical characteristics and radiological findings of participants included in the study cohort
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based on urine steroid metabolomics was consistently 
associated with lower false-positive rates (appendix 
pp 26–28). Imaging performance was generally better in 
non-ACC tumours smaller than 4 cm than in those 4 cm or 
larger. Unenhanced CT had a higher true-positive rate for 
ACC than a urine steroid metabolomics result indicating 
high risk of ACC (appendix p 26); MRI or ¹⁸F-FDG PET 
were used to assess very few ACCs (appendix pp 27−28), 
precluding comparisons with these methods.
247 (12·2%) of 2017 participants had positive results for 
tumour diameter and imaging characteristics. Among 
these, 95 of the 98 ACCs were true positives, leaving 152 
false-positive results (figure 3). Participants with a urine 
steroid metabolomics result indicating a high risk of ACC 
and a positive result for either tumour diameter or 
imaging characteristics increased the PPV for ACC 
compared with having combined positive tumour 
diameter and imaging characteristic results (table 2, 
figure 3, appendix p 29). When urine steroid metabolomics 
was combined with tumour diameter, only four 
participants with ACC were dismissed, and when 
combined with imaging characteristics only three were 
dismissed (table 2).
In the triple testing strategy, a result of tumour diameter 
larger than 4 cm, positive imaging characteristics (attenu-
ation >20 HU), and a urine steroid metabolomics result 
indicating high risk of ACC, yielded a group of 
106 participants, including 81 of the 98 participants with 
ACC (figure 3), giving a PPV for ACC of 76·4% (table 2). 
The triple testing strategy classified 70 participants as 
having moderate risk of ACC, including 12 of the 
98 participants with ACC (PPV 17·1%, table 2). The ability 
of the triple testing strategy to rule out ACC was high 
(table 2).
In a sensitivity analysis, when participants with mixed 
or aberrant steroid excess (n=42), clinical presentation of 
large adrenal mass with extra-adrenal metastases (n=13), 
and bilateral macronodular adrenal hyperplasia and 
isolated cortisol excess (n=22) were excluded, the high 
accuracy of urine steroid metabolomics compared with 
imaging was confirmed, as was the improvement of 
accuracy when urine steroid metabo lomics was used in 
combination with imaging modalities (appendix 
pp 16, 30–32).
Among the 65 non-ACC malignant tumours, 
46 (70·8%) had a tumour diameter greater than 4 cm, 
63 (97·0%) had positive imaging characteristics, and 
seven (10·8%) had a urine steroid metabolomics profile 
indicating high risk of ACC. These tumours could not be 
reliably differentiated from ACA and other benign 
tumours with any of the combined testing strategies 
(appendix pp 17, 33–35)
Discussion
Our results have validated the diagnostic utility of urine 
steroid metabolomics in detecting ACC in participants 
with newly diagnosed adrenal masses. Diagnostic 
accuracy of urine steroid metabolomics was high 
compared with maximum tumour diameter and imaging 
characteristics, and the best performance was seen when 
these three methods were combined. We also showed 
that using a cutoff of 20 HU for unenhanced CT tumour 
attenuation increases the accuracy of imaging character-
istic assess ment for exclusion of ACC compared with the 
currently recommended cutoff of 10 HU, which has 
immediate implications for clinical practice.
1686 (83·6%) of the adrenal tumours in our study cohort 
had been discovered incidentally, yielding to our knowledge 
the largest prospective cohort of partici pants with adrenal 
incidentaloma. We achieved this study size via a compre-
hensive, multicentre, non-selective approach, completing 
recruitment in 5·5 years. This cohort size compares 
favourably with the largest retrospective adrenal incidental-
oma cohort, in which 1096 patients were identified over a 
15-year period (1980–95).10 The distribution of underlying 
pathologies in our cohort was similar to those in 
retrospective studies,10,11 showing the representa tiveness of 
our cohort for clinical practice.
96 of 98 ACCs in our study were larger than 4 cm. 
This cutoff was previously suggested to be sensitive (93%) 
Figure 2: Imaging test results 
Maximum tumour diameter in patients with ACC (A), other malignant tumours (B), ACA (C), and other benign 
tumours (D) and distributions of patients with ACC according to positive or negative results for tumour diameter 
and imaging characteristics with unenhanced CT tumour attenuation cutoff of 10 HU (E) or 20 HU (F). 
ACA=adrenocortical adenoma. ACC=adrenocortical carcinoma. HU=Hounsfield units.
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for differentiating ACC from ACA, but to have poor 
specificity.10,11,15,17,22 Given the non-selective nature of 
recruitment in EURINE-ACT and the small number of 
ACCs less than 4 cm in diameter, growth velocity of these 
tumours seems to be very rapid, making early-stage 
detection unlikely. 1549 (76·8%) of participants in the 
study underwent unenhanced CT. Only one ACC had 
attenuation below 20 HU, giving this cutoff considerably 
improved specificity compared with the 10 HU cutoff 
recommended in the European guide lines.11,15−17 Applying 
cutoffs of 4 cm for maximum tumour diameter and 
20 HU for unenhanced CT tumour attenuation would, 
therefore, help to avoid unnecessary imaging procedures 
and adrenalectomies.
ACC 
(n=98)
Other 
malignant 
tumours 
(n=65)
All non-ACC 
tumours 
(n=1919)
ACA 
(n=1767)
Other 
benign 
tumours 
(n=87)
Total 
(n=2017)
Percentage of ACC 
cases (95% CI)
Percentage of 
non-ACC cases 
(95% CI)
Likelihood ratio 
(95% CI)
Post-test 
probability of 
ACC (per 
100 participants 
with results)
Single-test strategies
Tumour diameter
≥4 cm 96 46 392 296 50 488 98·0% (92·8–99·8)* 20·4% (18·6–22·3) 4·8 (4·4–5·3) 19·7 (16·2–23·5)
<4 cm 2 19 1527 1471 37 1529 2·0% (0·2–7·2) 79·6% (77·7–81·4)† 0·03 (0·01–0·10) 0·1 (0·0–0·5)
Imaging characteristics‡
Positive 97 63 396 289 44 493 99·0% (94·4–100·0)* 20·6% (18·8–22·5) 4·8 (4·4–5·3) 19·7 (16·3–23·5)
Negative 1 2 1523 1478 43 1524 1·0% (0·0–5·6) 79·4% (77·5–81·2)† 0·01 (0·00–0·09) 0·1 (0·0–0·4)
Urine steroid metabolomics
High risk of ACC 83 7 157 143 7 240 84·7% (76·0–91·2) 8·2% (7·0–9·5) 10·4 (8·7–12·3) 34·6 (28·6–41·0)
Moderate risk of 
ACC
13 28 655 578 49 668 13·3% (7·3–21·6) 34·1% (32·0–36·3) 0·39 (0·23–0·65) 1·9 (1·0–3·3)
Low risk of ACC 2 30 1107 1046 31 1109 2·0% (0·2–7·2) 57·7% (55·4–59·9) 0·04 (0·01–0·14) 0·2 (0·0–0·6)
Combined-test strategies
Tumour diameter and imaging characteristics‡
≥4 cm and positive 95 45 152 83 24 247 96·9% (91·3–99·4)* 7·9% (6·8–9·2) 12·2 (10·5–14·3) 38·5 (32·4–44·8)
<4 cm, negative, or 
both 
3 20 1767 1684 63 1770 3·1% (0·6–8·7) 92·1% (90·8–93·2)† 0·03 (0·01–0·10) 0·2 (0·0–0·5)
Tumour diameter and urine steroid metabolomics
≥4 cm and high risk 
of ACC
82 7 46 33 6 128 83·7% (74·8–90·4) 2·4% (1·8–3·2) 34·9 (25·9–47·1) 64·1 (55·1–72·3)
≥4 cm and 
moderate risk of 
ACC 
12 20 130 85 25 142 12·2% (6·5–20·4) 6·8% (5·7–8·0) 1·8 (1·0–3·2) 8·5 (4·4–14·3)
<4 cm, low risk of 
ACC, or both
4 38 1743 1649 56 1747 4·1% (1·1–10·1) 90·8% (89·4–92·1) 0·04 (0·02–0·12) 0·2 (0·0–0·6)
Imaging characteristics‡ and urine steroid metabolomics
Positive and high 
risk of ACC
82 6 43 35 2 125 83·7% (74·8–90·4) 2·2% (1·6–3·0) 37·3 (27·4–50·8) 65·6 (56·6–73·9)
Positive and 
moderate risk of 
ACC
13 28 155 97 30 168 13·3% (7·3–21·6) 8·0% (6·9–9·4) 1·69 (1·00–2·87) 7·7 (4·2–12·9)
Negative, low risk 
of ACC, or both
3 31 1721 1635 55 1724 3·1% (0·6–8·7) 89·7% (88·2–91·0) 0·03 (0·01–0·10) 0·2 (0·0–0·5)
Tumour diameter, imaging characteristics‡, and urine steroid metabolomics
≥4 cm, positive, 
and high risk of 
ACC
81 6 25 17 2 106 82·7% (73·7–89·6) 1·3% (0·8–1·9) 63·4 (42·5–94·6) 76·4 (67·2–84·1)
≥4 cm, positive, 
and moderate risk 
of ACC
12 20 58 23 15 70 12·2% (6·5–20·4) 3·0% (2·3–3·9) 4·1 (2·3–7·3) 17·1 (9·2–28·0)
<4 cm, negative, 
low risk of ACC, or 
a combination
5 39 1836 1727 70 1841 5·1% (1·7–11·5) 95·7% (94·7–96·5) 0·05 (0·02–0·13) 0·3 (0·0–0·6)
Data in columns one to six are numbers of participants. ACC=adrenocortical carcinoma. ACA=adrenocortical adenoma. *Sensitivity. †Specificity. ‡Positive was classified as unenhanced CT attenuation 
>20 Houndsfield units in homogeneous tumours or heterogeneous tumours precluding measurement of attenuation.
Table 2: Performance of tests and combination test strategies
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PPV was greater with urine steroid metabolomics than 
with tumour diameter and imaging characteristics. 
Combination of all three approaches gave the best overall 
detection of ACC, even when ACC tumours potentially 
identifiable by other parameters, such as mixed or aberrant 
steroid patterns or clinical presentations, were excluded. 
Based on our triple test strategy in the whole study cohort 
(n=2017), following the initial scan that provided tumour 
size measurements, only 488 participants (24·2%) would 
have required further imaging. Additionally, participants 
with a urine steroid metabolomics result indicating high 
risk of ACC could have undergone surgery for ACC earlier 
and fewer unnecessary surgeries for benign tumours 
would have been done. For participants with urine steroid 
meta bolomics results indicating moderate risk of ACC in 
the triple strategy, the PPV was 17%. Rather than blanket 
surgical removal, these participants could be managed 
individually, such as with detailed re-review of scans by a 
multi disciplinary team and consideration of biopsy. 
Although histopathology of an adrenal biopsy cannot 
differentiate between ACC and ACA, it can be informative 
in patients with other benign and malignant adrenocortical 
tumours, including metastases of extra-adrenal cancers.
Strengths of our study include its prospective, consecu-
tive, and non-selective recruitment, and the relatively short 
time needed for recruitment (avoiding biases due to change 
in diagnostic technologies and standards). Our previous 
proof-of-principle study of urine steroid metabolomics for 
ACC detection involved urinary steroid profiling by gas 
chromatography-mass spectrometry, which is a low-
throughput method requiring highly specialised expertise.18 
In this study, we used the high-throughput LC–MS/MS 
approach, which is much more widely available. Although 
a similar multisteroid profiling method has been described 
elsewhere,23 our method includes a machine-learning 
algorithm that was trained on steroid data measured by 
LC–MS/MS in a retrospective cohort, precluding error due 
to non-standardised assess ment of steroid profiling results. 
Other strengths of our study include the exclusion of 
participants under going imaging for cancer monitoring 
and the non-communication of urine steroid metabolomics 
results to clinical centres so as not to influence the usual 
diagnostic process.
Weaknesses of this study include its observational 
nature; notably, recruitment centres could use their 
preferred imaging modalities and, therefore, the numbers 
assessed by MRI or ¹⁸F-FDG PET were too low for compre-
hensive assessment. Participating centres were specialist 
adrenal tumour centres, but in non-specialised secondary 
care settings the proportions of large and malignant 
tumours might be lower. Histopathology was done only 
for participants who had surgery or biopsy, meaning that 
our reference standard was heterogeneous. However, it 
was of higher quality than most earlier diagnostic 
studies15,24 and is representative of clinical practice. We did 
not do a centralised pathology review, but as the study 
sites were high-volume specialist centres with established 
adrenal pathology expertise, all pathologists applied rele-
vant multifactorial scoring systems for assess ment of 
malignant potential in adrenal cortical neoplasms.25,26
In conclusion, our findings suggest that use of urine 
steroid metabolomics in diagnostic pathways could 
improve detection of ACC. We recommend a combined 
testing strategy of assessment with unenhanced CT, with 
a tumour attenuation cutoff of 20 HU, and urine steroid 
Figure 3: Diagnostic accuracy of single-test and multiple-test strategies for detecting ACC
(A) Diagnostic accuracy of the three index tests (tumour diameter, imaging characteristics [unenhanced CI 
attenuation >20 HU], and urine steroid metabolomics) as single tests, in double combinations, and as a triple-test 
strategy. (B) Flowchart illustrating the distribution of ACC cases  when applying the triple-test strategy in the order: 
tumour diameter, imaging characteristics (unenhanced CT attenuation >20 HU), and urine steroid metabolomics. 
ACC=adrenocortical carcinoma. HU=Hounsfield units. ImChar=imaging characteristics. USM-HR=urine steroid 
metabolomics profile indicating high risk of ACC. USM-LR=urine steroid metabolomics profile  indicating low risk 
of ACC. USM-MR=urine steroid metabolomics profile indicating moderate risk of ACC.
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metabolomics. We anticipate that these changes would 
substantially lessen the burden on and morbidity in 
patients with benign adrenal tumours and suspicious 
imaging findings, and lead to reductions in health-care 
costs due to decreased numbers of imaging procedures, 
time to surgery in ACC, and numbers of unnecessary 
surgeries.
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